Should I buy or sell Axsome Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks .

What is Axsome Therapeutics' stock price target for 2024?

9 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' stock. Their AXSM share price targets range from $81.00 to $180.00. On average, they anticipate the company's stock price to reach $105.50 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts .

How have AXSM shares performed in 2023?

Axsome Therapeutics' stock was trading at $77.13 at the beginning of 2023. Since then, AXSM stock has decreased by 11.1% and is now trading at $68.59. View the best growth stocks for 2023 here .

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our AXSM earnings forecast .

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its earnings results on Monday, November, 6th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $0.08. The company earned $57.79 million during the quarter, compared to the consensus estimate of $54.88 million. Axsome Therapeutics had a negative net margin of 90.33% and a negative trailing twelve-month return on equity of 88.79%. During the same period in the previous year, the business posted ($1.03) EPS.

What ETFs hold Axsome Therapeutics' stock?

ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , ALPS Medical Breakthroughs ETF (SBIO) , Virtus LifeSci Biotech Products ETF (BBP) , iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC) . First Trust Nasdaq Pharmaceuticals ETF (FTXH) .

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Dicerna Pharmaceuticals (DRNA) , Amarin (AMRN) , Sarepta Therapeutics (SRPT) , Micron Technology (MU) , Pfizer (PFE) , AbbVie (ABBV) , Alibaba Group (BABA) and Bristol-Myers Squibb (BMY) .

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (9.49%), FMR LLC (3.93%), Alethea Capital Management LLC (1.60%), Northern Trust Corp (0.74%), Eventide Asset Management LLC (0.73%) and Adage Capital Partners GP L.L.C. (0.69%). Insiders that own company stock include Mark Coleman , Mark E Saad , Nick Pizzie and Roger Jeffs . View institutional ownership trends .

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Axsome Therapeutics Stock Price, News & Analysis (NASDAQ:AXSM)

$68.59

+1.16 (+1.72%)

(As of 12/5/2023 ET)

Compare

Today's Range: $67.16
▼
$69.31
50-Day Range: $57.42
▼
$73.06
52-Week Range: $53.71
▼
$91.29

Volume: 386,359 shs
Average Volume: 827,326 shs
Market Capitalization: $3.25 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $105.50

Axsome Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 53.8% Upside
$105.50 Price Target
Short Interest: Bearish
16.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.03
Upright™ Environmental Score
News Sentiment: 0.50
Based on 2 Articles This Week
Insider Trading: Selling Shares
$828,293 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.06) to ($3.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

296th out of 948 stocks

Pharmaceutical Preparations Industry

115th out of 421 stocks

3.4

Analyst's Opinion

Consensus Rating
Axsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $105.50, Axsome Therapeutics has a forecasted upside of 53.8% from its current price of $68.59.
Amount of Analyst Coverage
Axsome Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
16.15% of the outstanding shares of Axsome Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Axsome Therapeutics has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Axsome Therapeutics has recently increased by 3.95%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Axsome Therapeutics does not currently pay a dividend.
Dividend Growth
Axsome Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Axsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.
Environmental Sustainability
The Environmental Impact score for Axsome Therapeutics is -1.03.

2.5

News and Social Media Coverage

News Sentiment
Axsome Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Axsome Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 12 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
MarketBeat Follows
5 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $828,293.00 in company stock.
Percentage Held by Insiders
24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
76.60% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.06) to ($3.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Axsome Therapeutics is -15.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Axsome Therapeutics is -15.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Axsome Therapeutics has a P/B Ratio of 27.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Axsome Therapeutics Stock (NASDAQ:AXSM)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AXSM Stock News Headlines

December 3, 2023 | barrons.com

UPCOMING AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

November 27, 2023 | seekingalpha.com

Axsome Therapeutics: Positive Q3, We Like The Launch Success Story

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

November 22, 2023 | finance.yahoo.com

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

November 21, 2023 | finance.yahoo.com

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

November 8, 2023 | markets.businessinsider.com

Buy Rating on Axsome Therapeutics: Financial Growth and Promising Pipeline despite Minor Setbacks

November 7, 2023 | markets.businessinsider.com

Hold Rating on Axsome Therapeutics: Unchanged Strategies and Revenue Forecasts Amid Concerns on Future Sales and Profitability Trends

November 7, 2023 | finance.yahoo.com

Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

November 7, 2023 | finance.yahoo.com

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call Transcript

November 7, 2023 | finance.yahoo.com

Q3 2023 Axsome Therapeutics Inc Earnings Call

November 7, 2023 | seekingalpha.com

Axsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade)

November 7, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Sangamo Biosciences (SGMO), Axsome Therapeutics (AXSM)

November 6, 2023 | finance.yahoo.com

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023 | finance.yahoo.com

Axsome Therapeutics Inc (AXSM) Reports 244% YoY Growth in 3Q 2023 Product Revenue

November 2, 2023 | finance.yahoo.com

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

October 30, 2023 | finance.yahoo.com

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

October 24, 2023 | finance.yahoo.com

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

October 17, 2023 | markets.businessinsider.com

Buy Rating Assigned to Axsome Therapeutics Amid Positive Prescription Trends for Auvelity

October 16, 2023 | seekingalpha.com

Axsome Update: Buy At Dips And Hold Forever

October 12, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Cytokinetics (CYTK), Axsome Therapeutics (AXSM)

October 11, 2023 | finance.yahoo.com

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

October 10, 2023 | finance.yahoo.com

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

October 9, 2023 | markets.businessinsider.com

Truist Financial Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

October 4, 2023 | msn.com

Mizuho says market fears for Harmony's Wakix drug are "overblown"

October 3, 2023 | markets.businessinsider.com

Maintaining Buy Rating for Axsome Therapeutics: Steady Auvelity Sales and Anticipated Q3 Performance Insights

October 2, 2023 | finance.yahoo.com

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

See More Headlines

Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AXSM
CUSIP: N/A
CIK: 1579428
Web: axsome.com
Phone: (212) 332-3241
Fax: 212-320-0245
Employees: 502
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $105.50
High Stock Price Target: $180.00
Low Stock Price Target: $81.00
Potential Upside/Downside: +53.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-187,130,000.00
Net Margins: -90.33%
Pretax Margin: -89.75%
Return on Equity: -88.79%
Return on Assets: -35.35%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 4.46
Quick Ratio: 4.38

Sales & Book Value

Annual Sales: $50.04 million
Price / Sales: 64.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.52 per share
Price / Book: 27.22

Miscellaneous

Outstanding Shares: 47,320,000
Free Float: 35,727,000
Market Cap: $3.25 billion
Optionable: Optionable
Beta: 1.94

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Herriot Tabuteau M.D. (Age 55)
Founder, Chairman, CEO & President
Comp: $1.32M
Mr. Nick Pizzie CPA (Age 48)
M.B.A., Chief Financial Officer
Comp: $732.94k
Mr. Mark L. Jacobson (Age 40)
COO & Secretary
Comp: $784.66k
Mr. Hunter Murdock Esq. (Age 43)
General Counsel & Secretary
Comp: $735.39k
Dr. Amanda Jones Pharm.D. (Age 40)
Senior Vice President of Clinical Development
Ms. Lori Englebert M.B.A. (Age 45)
Executive Vice President of Commercial & Business Development
Joseph Debrah-Afful CPA
M.B.A., Director of Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.
What is Axsome Therapeutics' stock price target for 2024?: 9 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' stock. Their AXSM share price targets range from $81.00 to $180.00. On average, they anticipate the company's stock price to reach $105.50 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.
How have AXSM shares performed in 2023?: Axsome Therapeutics' stock was trading at $77.13 at the beginning of 2023. Since then, AXSM stock has decreased by 11.1% and is now trading at $68.59.
View the best growth stocks for 2023 here.
When is Axsome Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our AXSM earnings forecast.
How were Axsome Therapeutics' earnings last quarter?: Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its earnings results on Monday, November, 6th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $0.08. The company earned $57.79 million during the quarter, compared to the consensus estimate of $54.88 million. Axsome Therapeutics had a negative net margin of 90.33% and a negative trailing twelve-month return on equity of 88.79%. During the same period in the previous year, the business posted ($1.03) EPS.
What ETFs hold Axsome Therapeutics' stock?: ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH).

What other stocks do shareholders of Axsome Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).
When did Axsome Therapeutics IPO?: (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
Who are Axsome Therapeutics' major shareholders?: Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (9.49%), FMR LLC (3.93%), Alethea Capital Management LLC (1.60%), Northern Trust Corp (0.74%), Eventide Asset Management LLC (0.73%) and Adage Capital Partners GP L.L.C. (0.69%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends.
How do I buy shares of Axsome Therapeutics?: Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AXSM) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Axsome Therapeutics Stock Price, News & Analysis (NASDAQ:AXSM)

Axsome Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Axsome Therapeutics Stock (NASDAQ:AXSM)

AXSM Stock Price History

AXSM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AXSM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™